Benevolent AI (BAI) EUR1 A
BenevolentAI SA is an artificial intelligence (AI)-enabled drug discovery and development company. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, it delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers its in-house drug pipeline and supports collaborations with AstraZeneca, as well as research and charitable institutions. Its pipeline includes BEN-2293, BEN-8744, BEN-9160 and BEN-28010. It integrates data from across domains and data types, including omics, molecules, experiments, literature, pathology and biological systems to provide a holistic view of biology. BEN-8744 is under development as an ulcerative colitis treatment for a novel target discovered using its AI platform. BEN-2293 is a topical PanTrk inhibitor in development to relieve inflammation and rapidly resolve itch in patients with atopic dermatitis.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.